SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.7405
-0.0341 (-4.40%)
At close: Jan 29, 2026, 4:00 PM EST
0.7386
-0.0019 (-0.26%)
After-hours: Jan 29, 2026, 5:18 PM EST
SCYNEXIS Employees
SCYNEXIS had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change (1Y)
-1
Growth (1Y)
-3.45%
Revenue / Employee
$104,714
Profits / Employee
-$903,571
Market Cap
31.08M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2023 | 29 | -7 | -19.44% |
| Dec 31, 2022 | 36 | -20 | -35.71% |
| Dec 31, 2021 | 56 | 18 | 47.37% |
| Dec 31, 2020 | 38 | 11 | 40.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 320 |
| Zhengye Biotechnology Holding | 277 |
| Rockwell Medical | 244 |
| Cumberland Pharmaceuticals | 91 |
| Aytu BioPharma | 83 |
| Assertio Holdings | 58 |
| BioXcel Therapeutics | 37 |
| Talphera | 13 |
SCYX News
- 5 weeks ago - SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire
- 2 months ago - SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - GlobeNewsWire
- 3 months ago - SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study - GlobeNewsWire
- 5 months ago - SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) - GlobeNewsWire
- 6 months ago - SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - GlobeNewsWire
- 11 months ago - SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire